JO

John Osborn

Venture Partner at BioVentures Investors

Chadds Ford, Pennsylvania

Overview 

John Osborn is a Fortune 1000 general counsel and life sciences board member with a background in the US State Department, known for his expertise in regulatory compliance, acquisitions, public policy, and crisis management. Currently, he serves as a Senior Advisor at Hogan Lovells and a Venture Partner at BioVentures Investors, while also contributing as a writer for Forbes and advising various organizations like Atostek and Real Chemistry.

Work Experience 

  • Senior Advisor

    2013 - Current

    Advise on corporate, commercial, public policy and regulatory matters for life sciences and healthcare industry clients of this leading global law firm

Hogan Lovells is a London-based multinational law firm that provides legal advisory services.

  • Venture Partner

    2018

    Growth and venture stage investments in innovative medtech companies

Bioventures Investors is an investment firm focused on the commercial development of advanced technology in life sciences and healthcare.

  • Contributor

    2013

Forbes Magazine is a business magazine that is focused on business news and financial information.

Raised $200,000,000.00 from Binance.

  • Affiliate Professor

    2012

    Also occasional guest lecturer at the UW Foster School of Business

  • Guest Lecturer

    1997

    Lecturer in The Business of Biology, an interdisciplinary graduate course

  • Visiting Scholar and Guest Lecturer

    2018

    Dep't of Health Policy & Management, UCLA Seminar on Pharmaceutical Policy & Economics

  • Executive-in-Residence and Industry Advisor

    2013 - 2016

    Advised the healthcare and consumer group of leading private equity firm on prospective transactions and portfolio company investments

Warburg Pincus is a private equity firm focused on growth investing.

Raised $38,028,202.00.

  • Senior Vice President, Global Corporate Affairs

    2012 - 2013

    Responsible for government affairs, public policy, patient advocacy, corporate communications, investor relations, and social media for this biopharmaceutical company prior to its acquisition by Amgen

Onyx Pharmaceuticals is a biopharmaceutical company committed to improving the lives of people with cancer.

Raised $20,000,000.00 from OrbiMed, Perceptive Life Sciences, Federated Kaufmann Fund and Domain Associates.

  • Executive Vice President, General Counsel & Secretary

    2011 - 2012

    Innovative biotechnology company that developed and launched the first approved active cellular immunotherapy for the treatment of metastatic prostate cancer

  • Commissioner

    2008 - 2011

    Nominated by President George W. Bush and confirmed by the Senate to bipartisan presidential commission responsible for evaluating the effectiveness of our policies and programs in public diplomacy

Articles About John

Relevant Websites